2026年7月1日-10日，全球医药市场共签署了30项资产授权和合作协议。中国市场共达成15项交易，包括4项引进交易、6项出海交易和5项国内交易。
国内市场上，本周最大的引进交易是康恩贝从Adneuris Therapeutics引进临床三期资产cebranopadol在大中华地区的开发与商业化权益，首付款1750万美元，总金额可达1.115亿美元。最大的出海交易是正大天晴与AstraZeneca就临床三期资产TQC3721订立独家授权协议，首付款2亿美元，总金额可达21亿美元。最大的国内交易是海正药业与艾缇亚就临床二期资产UP-818-CC签署独家授权许可及合作协议，首付款630万美元，总金额可达6200万美元。
国际市场上，本周共签署了15项资产授权和合作协议。首付款最大的交易是Astex Pharmaceuticals与Genentech就乳腺癌治疗药物研发签订全球独家研究合作和许可协议，首付款2500万美元，总金额可达4.9亿美元。
From July 1 to 10, a total of 30 agreements were signed worldwide. Within China’s biotech industry, there were four in-licensing deals, six out-licensing deals and five domestic transactions.
In China, the largest in-licensing deal involved Adneuris Therapeutics and Conba Pharmaceutical for the phase 3 asset cebranopadol, with an upfront payment of $17.5 million and a total deal value of $111.5 million. The largest out-licensing deal was between Chia Tai Tianqing Pharmaceutical and AstraZeneca for the Phase 3 asset TQC3721, with an upfront payment of $200 million and a total deal value of $2.1 billion. The largest domestic deal was between EnliTISA and Hisun Pharmaceutical for the phase 2 asset UP-818-CC, including an upfront payment of $6.3 million and a total deal value of $62 million.
Globally, 15 deals were announced. The largest transaction was between Astex Pharmaceuticals and Genentech for breast cancer therapy program, with an upfront payment of $25 million and a total deal value of $490 million.
3. M&A Deals
4. Top Deals of 2026
